US Bancorp DE lowered its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 17.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,856 shares of the company’s stock after selling 386 shares during the period. US Bancorp DE’s holdings in VanEck Pharmaceutical ETF were worth $176,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Optimum Investment Advisors bought a new stake in shares of VanEck Pharmaceutical ETF during the 2nd quarter valued at about $27,000. GPS Wealth Strategies Group LLC purchased a new position in VanEck Pharmaceutical ETF in the 2nd quarter worth approximately $42,000. CWM LLC purchased a new stake in shares of VanEck Pharmaceutical ETF during the 2nd quarter valued at $55,000. International Assets Investment Management LLC purchased a new stake in shares of VanEck Pharmaceutical ETF during the 2nd quarter valued at $86,000. Finally, Comerica Bank lifted its holdings in shares of VanEck Pharmaceutical ETF by 39.4% during the 1st quarter. Comerica Bank now owns 1,337 shares of the company’s stock worth $121,000 after acquiring an additional 378 shares during the last quarter.
VanEck Pharmaceutical ETF Stock Down 1.5 %
PPH opened at $88.17 on Friday. The business’s fifty day simple moving average is $93.88 and its 200 day simple moving average is $92.99. VanEck Pharmaceutical ETF has a 52 week low of $76.31 and a 52 week high of $99.51. The stock has a market cap of $651.58 million, a PE ratio of 21.04 and a beta of 0.72.
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- Compound Interest and Why It Matters When Investing
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- How to Effectively Use the MarketBeat Ratings Screener
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
